KR102461681B1 - Pharmaceutical and food composition for treating or alleviating influenza a - Google Patents

Abstract

An antiviral agent exhibiting an improving effect on influenza A virus is disclosed. The antiviral agent according to the present invention includes maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.

Description

Antiviral agent for the treatment or alleviation of influenza A virus {PHARMACEUTICAL AND FOOD COMPOSITION FOR TREATING OR ALLEVIATING INFLUENZA A}

The present invention relates to an antiviral agent, and more particularly, to an antiviral agent that exhibits an effect of improving symptoms on influenza A virus.

How not to get sick and how to overcome the disease are mostly the same. One of the methods is to increase immunity to pathogenic microorganisms and to fight pathogenic microorganisms. Pathogenic microorganisms include viruses, bacteria, fungi, acarus folliculorum, and the like. Among these, in particular, the virus is one that modern medicine has not yet accurately identified and has not been able to properly respond to. The present inventors have speculated that many diseases for which modern medicine cannot provide a proper treatment are caused by viral infection, and have confirmed that this assumption is true while applying the antiviral agent according to the present invention to many patients. Therefore, in the future, eradication of viruses will play a key role in overcoming many diseases.

On the other hand, it is difficult to determine whether a virus is pathogenic due to its characteristics. Even if a vaccine or therapeutic agent is found, the expression of a resistant virus is easy, so it is very difficult to continuously show a therapeutic effect. In addition, viruses, by their nature, parasitize in the cells of the host, and if the immunity of the host is strong, dormant in the cells to avoid contact with the immune cells, and only when the immunity of the host is weakened, they come out of the cells and show pathogenicity. Therefore, unlike bacteria or fungi, viruses often do not show any pathological symptoms due to inactivity even though they are infected, making it difficult to determine whether the virus is pathogenic. At a time when information on bacteria was scarce, tuberculosis and leprosy were sometimes mistaken for hereditary diseases. Although some diseases are viral diseases, they are mistaken for a disease caused by a genetic disease or a family history because the discovery of the virus or the pathogenicity of the virus is not known.

Viruses are parasitic in living cells, and their small size and simple structure make them highly susceptible to mutation. Because new strains and strains are constantly emerging, there are far more unknown types than known types. Because the emergence of new or mutated viruses is frequent and difficult to predict, the development of vaccines is difficult. Due to the frequent appearance of mutated viruses, it is often difficult for antiviral drugs that have been developed with difficulty to continuously exhibit therapeutic effects.

Conventionally, different antiviral agents have been developed and applied for each type of virus. For viral diseases such as avian influenza (influenza), severe acute respiratory syndrome, novel influenza (influenza), and Middle East respiratory syndrome coronavirus, vaccines or therapeutic agents that are uniquely effective for individual diseases are being developed. However, these vaccines or therapeutic agents are not effective against mutated viruses or newly emerged viruses.

Accordingly, there is a need to develop foods capable of improving or curing symptoms of various types of viral diseases or diseases suspected of being viral diseases.

U.S. Patent Publication No. 2004/0091555 A1 discloses a method for producing an extract of dragon fruit extract exhibiting an antiviral effect against hepatitis B virus and a food antiviral agent containing the extract. However, the dragon fruit extract only exerts an effective effect on the hepatitis B virus, and does not exert an effect on other types of viral diseases or diseases suspected of being viral diseases.

Patent Registration Publication No. 10-1627065 (Registration Date: 2016.05.27)

An object of the present invention is to provide an antiviral agent capable of improving the symptoms of influenza A virus disease.

The above-described object of the present invention, maple syrup, tabasheer, uiiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis, it can be achieved by an antiviral agent comprising a powder, liquid or extract form.

Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, extract of frankincense, myrrh, can be made into pills or granules by further mixing manuka honey in the mixed powder of the extract.

The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.

The antiviral agent according to the present invention is hepatitis B, hepatitis C, herpes zoster, adenovirus, rhinovirus, influenza, avian influenza, severe acute respiratory syndrome, novel influenza, Middle East respiratory It is also effective in improving symptoms of known viral diseases such as syndrome coronavirus and cold viruses. In addition, the antiviral agent according to the present invention has an effect of improving or curing the symptoms of the following diseases suspected as viral diseases.

1) If pain is continuously and repeatedly in the same area, such as fibromyalgia, chronic musculoskeletal pain, and chronic myofascial pain, it is presumed to be infected with the virus. The antiviral agent according to the present invention has an effect of improving or curing a condition that continuously and repeatedly causes pain in the same site, such as when fibromyalgia, chronic musculoskeletal pain, chronic myofascial pain, etc. become chronic.

2) If persistent and repetitive lesions are induced in the same area, such as atopic dermatitis and allergic rhinitis, it is presumed to be infected with the virus. The antiviral agent according to the present invention has an effect of improving or curing a condition in which continuous and repetitive lesions are induced in the same site, such as atopic dermatitis, allergic rhinitis, and the like.

3) Most diseases belonging to allergies or autoimmune diseases are presumed to be infections caused by viruses. The antiviral agent according to the present invention has an effect of improving or curing most diseases or conditions belonging to allergies or autoimmune diseases.

4) As with psoriasis, if the inflamed area is slightly red in color due to inflammation, but it does not purify easily and the inflammation continues and the severity of symptoms repeats, it is presumed to be infected with a virus. The antiviral agent according to the present invention has an effect of improving or curing a condition that repeats the severity of the symptoms while being continuously maintained without being easily purulent although the color of the inflamed area is slightly red due to inflammation.

5) Chronic inflammation that occurs repeatedly and continuously in the mucous membranes of the eyes, nose, mouth, gums (periodontal), neck, stomach, small intestine, large intestine, bladder, and female genitalia is presumed to be a viral infection. The antiviral agent according to the present invention improves or improves chronic inflammation that occurs repeatedly and continuously in mucosal sites exposed to the outside such as eyes, nose, mouth, gums (periodontal), neck, stomach, small intestine, large intestine, bladder, female genitalia, etc. It has a healing effect.

6) Some of the adult diseases or lifestyle diseases such as diabetes and high blood pressure are presumed to be caused by virus infection in the relevant area. The antiviral agent according to the present invention has an effect of improving or curing symptoms such as adult diseases or life style diseases, such as diabetes and hypertension, which are caused by viruses.

7) Diseases discussed as genetic diseases such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy are also speculated to be viral diseases of the central nervous system. The antiviral agent according to the present invention has an effect of improving or curing symptoms of diseases discussed as genetic diseases, such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy.

8) It is assumed that one of the causes of central nervous system diseases such as developmental disorder, brain lesion disorder, and dementia is infection by virus in the relevant area. The antiviral agent according to the present invention is effective in improving or curing conditions of central nervous system diseases such as developmental disorders, brain lesion disorders, and dementia.

The antiviral agent according to the present invention includes maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in powder, liquid or extract form.

The antiviral agent according to the present invention can be made into pills or granules by further mixing manuka honey, maple syrup and tabasheer in the mixed powder of uiin, xylitol, vitamin C, frankincense extract, myrrh, and propolis extract.

The antiviral agent according to the present invention may include an extract extracted from a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis as an active ingredient.

The compositional components of the present invention and the composition ratio between the components are as follows.

1) 1 to 30% by weight of concentrated maple syrup by collecting the sap of Canadian maple;

2) 1 to 30% by weight of bamboo sap, bamboo sap (natural bamboo flavor), evaporated by strong heat in the process of making charcoal from bamboo;

3) 5 to 60% by weight of Uiyin, a food ingredient known to have antibacterial properties (based on total weight, the same as below);

4) 10-40% by weight of xylitol, a food ingredient also known to have antibacterial properties;

5) 1 to 20% by weight of vitamin C, a nutritional supplement known as an antioxidant;

6) 1-20% by weight of Manuka honey, a food known to have antibacterial active substances;

7) 1 to 20% by weight of frankincense, a food known to have detoxifying properties;

8) 1 to 20% by weight of myrrh, a food known to have the function of removing eohyeol;

9) 0.1~10% by weight of propolis extracted from the beehive and used as a food ingredient.

When the uiiin is added in less than 5% by weight, the antiviral effect by the uiiin is insignificant, and when the uiiin is added in excess of 60% by weight, the increase in the antiviral effect by the uiiin is small, while adding the antiviral function by other materials It is difficult to make it effective against various types of viruses.

When maple syrup is added in less than 1% by weight, the antiviral effect by maple syrup is insignificant, and when maple syrup is added in excess of 30% by weight, the increase in the antiviral effect by maple syrup is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.

When the tabasheer is added to less than 1% by weight, the antiviral effect by tabasheer is insignificant, and when the tabasheer is added in excess of 30% by weight, the increase in the antiviral effect by tabasheer is small, while adding the antiviral function by other materials It is difficult to make it effective against various types of viruses.

When xylitol is added in an amount of less than 10% by weight, the antiviral effect by xylitol is insignificant, and when xylitol is added in excess of 40% by weight, the increase in the antiviral effect by xylitol is small, while adding antiviral function by other materials It is difficult to make it effective against various types of viruses.

When vitamin C is added in an amount of less than 1% by weight, the antiviral effect by vitamin C is insignificant, and when vitamin C is added in excess of 20% by weight, the increase in the antiviral effect by vitamin C is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.

When Manuka honey is added in an amount of less than 1% by weight, the antiviral effect by Manuka honey is insignificant, and when Manuka honey is added in excess of 20% by weight, the increase in the antiviral effect by Manuka honey is small, whereas the antiviral effect caused by other materials is small. Since it is difficult to add a function, it is difficult to have efficacy against various types of viruses.

When frankincense is added in an amount of less than 1% by weight, the antiviral effect of frankincense is insignificant, and when frankincense is added in excess of 20% by weight, the increase in the antiviral effect of frankincense is small, while adding the antiviral function by other materials. It is difficult to make it effective against various types of viruses.

When the amount of myrrh is added less than 1% by weight, the antiviral effect of myrrh is insignificant, and when the amount of myrrh exceeds 20% by weight, the increase in the antiviral effect of myrrh is small, while it is difficult to add the antiviral function by other materials. It is difficult to make it effective against a kind of virus.

When propolis is added in an amount of less than 0.1% by weight, the antiviral effect of propolis is insignificant, and when propolis is added in excess of 10% by weight, the increase in the antiviral effect by propolis is small, while the antiviral function by other materials Since it is difficult to add , it is difficult to have efficacy against various types of viruses.

Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, frankincense, and myrrh mixed powder, Manuka honey and propolis can be further mixed to make pills, granules, or powder for oral use.

The antiviral agent according to the present invention is a mixture of maple syrup, tabasheer, uiin, xylitol, vitamin C, frankincense extract, myrrh, and propolis extract, and Manuka honey is further mixed to form pills, granules, or powders for oral use. can make

Antiviral agent according to the present invention, maple syrup, tabasheer, uiin, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis mixed with water, or ethanol, or an extract extracted with water and ethanol as an active ingredient It can be made into pills, granules, powders, or liquids for oral use.

Maple syrup, which is concentrated by collecting the sap of Canadian maple trees, is currently being used as a substitute for sugar.

Bamboo power (natural bamboo flavor), It is a collection of bamboo sap that is evaporated by strong heat in the process of making charcoal from bamboo. The taste is sweet and the nature is cold. In oriental medicine, it is known that it works on the heart and stomach and relieves heat and phlegm.

Ui-in is the dried seed of Yulmu, a gramineae species. Yulmu is planted in various parts of Korea.

Xylitol is a pentose (C ₅ H ₁₂ O ₅ . molecular weight 152.15) extracted from birch bark and sap.

Vitamin C is an antioxidant that protects the body from free radicals to prevent cancer, arteriosclerosis, rheumatism, and strengthens the immune system.

Manuka honey is honey produced by the flowers of the Manuka tree, which is native to New Zealand, and collected by bees in a hive.

Frankincense is a condensed-dried resin exuding from the trunk and bark of frankincense, a tropical plant belonging to the olive family (Bursaceae).

Myrrh is derived from the stem of myrrh (myrra), a small tree in the family Burseraceae, and yellow juice exuding from the upper mouth of the skin. The oily resin (乳狀樹脂) is dried to form a reddish-brown mass.

Propolis is made by honey bees collecting resin from trees, grass, and flowers and mixing their saliva and secretions.

Among the components of the antiviral agent according to the present invention, maple syrup, tabasheer, uiiin, xylitol, manuka honey, frankincense, myrrh and propolis are those derived from living things in nature, and their individual antiviral effects are insignificant, but they can be combined. In this case, it shows a large synergistic effect, unexpected from the individual effects, for various viral diseases.

One of the characteristics of viral diseases is that they occur intensively in areas where contact with external substances is frequent, such as the skin and mucous membranes. Since most viruses are transmitted by contact, they are often infected on the skin or mucous membranes where contact with foreign substances or objects is frequent. Since the virus is difficult to penetrate directly into healthy skin, it is easy to infect through areas with an infection of acarus folliculorum, areas with inflammation, or areas with skin damage. The virus easily penetrates into any mucous membrane, so it can infect the inner wall of the nose, bronchial lining, mouth lining, stomach lining, small intestine lining, large intestine lining, anus lining, vaginal lining, uterine lining, cornea and conjunctiva of the eye, etc. Viruses that prefer specific cells may infect only a specific site. In the case of a virus that is friendly to a specific cell, such as hepatitis B virus, it infects only a specific site.

Another characteristic of viral diseases is that the symptoms do not get better and the symptoms repeat depending on the state of health. If immunity is normal, it survives only in cells and does not cause special lesions. Then, when immunity is weakened, it infects surrounding cells and causes unique lesions. As such, the symptoms of viral diseases do not get better and repeat and persist depending on the immune system.

Another characteristic of viral diseases is that it is difficult to find the causative virus. Bacterial diseases are easy to find the causative organism. However, in the case of a viral disease that causes chronic disease with weak pathogenicity, it usually hides in cells and does not cause inflammation. Viruses that cause specific diseases can be continuously found in the same area of patients with weakened immunity. Accordingly, the corresponding virus may be determined as the causative virus of a specific disease. However, the virus can also be found in a similar area of a normal person with strong immunity who has no experience of developing a specific disease. As a result, the virus cannot be concluded as the causative virus of a specific disease and can be classified as a non-pathogenic virus. On the other hand, when a disease having the above characteristics is assumed to be a viral disease, and the antiviral agent according to the present invention is applied, it was confirmed that the symptoms were improved or cured.

Known viral diseases include influenza, viral hepatitis, viral enteritis, herpes zoster, viral conjunctivitis, polio, and AIDS. , viral encephalopathy, measles, mumps, etc. Even in these viral diseases, there are many cases where a proper antiviral agent has not yet been developed.

Diseases that have all the characteristics of the viral diseases described above include the following.

autoimmune diseases such as vitiligo; allergic diseases such as atopic dermatitis; chronic pain disorders of the musculoskeletal system; sickness or stunting in infants and children; lifestyle diseases such as high blood pressure and diabetes; some infertility; developmental disorders, central nervous system diseases, such as brain lesion disorders; Diseases known as genetic disorders, such as Down's syndrome, Cri du chat syndrome, and Muscular Dystrophy; Dementia.

All of these diseases are either viral diseases or diseases associated with viral infections.

Autoimmune disease is a disease in which the exact cause of the disease is unknown, but the immune cells react to certain substances in the body and the inflammatory reaction continuously appears. Vitiligo, rheumatism, Crohn's disease, lupus, pemphigus ( pemphigus), etc. These diseases refer to a condition in which inflammation is continuously occurring due to an immune response in our body, and since bacteria or fungi are not found and the cause of inflammation cannot be found, they are named autoimmune diseases. Autoimmune diseases are diseases that show all the typical characteristics of the viral diseases described above. The inventors of the present invention speculate that autoimmune disease is not a disease in which an immune response is caused by a certain substance in the body and causes inflammation, but is a viral infection disease in which an immune response occurs at an infected site and inflammation occurs due to a viral infection.

Allergy and autoimmune disease are the same disease from the point of view of immune overreaction, and it is difficult to find a boundary as most organ-specific autoimmune diseases are included in type II allergy. To be distinguished, allergy (allergy) is one in which the substance of the antigen has been clearly identified, and one that has not yet been identified is autoimmune disease. However, the inventor of the present invention, for most allergies including atopy, a relatively weak virus enters the cell and makes the state of the cell sensitive, and another inflammatory substance, an antigen, stimulates the cell to induce an immune response. It is assumed to be a viral disease.

As with fibromyalgia and chronic musculoskeletal pain, when muscles or ligaments are damaged, immunity is weakened, and symptoms worsen if infected with a virus before damaged cells are fully recovered. In addition, due to the nature of viral inflammation, the inflammation does not heal cleanly and the symptoms continue to repeat. In this case, it has been confirmed through many clinical trials that the symptoms are surely improved with the antiviral agent according to the present invention and appropriate strengthening exercise for the affected area. In addition, it was confirmed through clinical practice that even if the muscle or ligament was damaged by an external shock or excessive exercise, which did not heal cleanly and caused repeated and continuous symptoms, it was a viral infection.

The inventors of the present invention speculate that the specific illness or stunting in infants and children is also a viral disease. Viral infection in young children can impede growth and development by causing various symptoms such as repeated cold symptoms, enlarged tonsils, poor growth, decreased physical strength, loss of appetite, and weakened digestive function. In this case, the eradication of the virus helps the sick child to grow and develop normally.

The inventors of the present invention speculate that hypertension and diabetes are also virus-related diseases. It is known that the cause of type 1 diabetes is that antibodies generated after viral infection such as mumps or rubella destroy the pancreas. However, in clinical cases of type 1 diabetic patients, a number of examples in which the antiviral agent according to the present invention acted as a key and reduced insulin were confirmed. In addition, among patients with poorly controlled type 2 diabetes or hypertension, clinical cases in which the antiviral agent according to the present invention is stable and managed to a certain extent are frequently experienced. It was speculated that there are many cases that act as a cause of exacerbation.

The inventors of the present invention speculate that infertility is also a disease associated with the virus. As mentioned earlier, the mucous membrane is a site prone to viral infection, and viral infections may occur frequently in the genital mucosa, and if the infection becomes severe, infertility may occur. Therefore, even in the case of infertile women, it is necessary to eradicate the virus while taking the antiviral agent according to the present invention. Through clinical cases, cases in which physical strength improves and pregnancy is successful just by eliminating the virus have been confirmed several times.

The inventors of the present invention speculate that central nervous system diseases such as developmental disorders and brain lesion disorders are also virus-related diseases. Developmental disorder (developmental disorder) is a disease that the inventors of the present invention guessed as a viral central nervous system disease through several clinical cases, and is a disease that continues to appear in clinical cases presumed to be a viral central nervous system disease. Although it has not yet been identified in modern medicine, it is assumed that diseases such as developmental disorders and brain lesion disorders are central nervous system diseases caused by viruses and are improved by the nerve regeneration process based on taking the antiviral agent according to the present invention. experienced several times. In addition, as the virus was eradicated, it was often confirmed that intelligence increased and symptoms improved.

The inventors of the present invention speculate that diseases such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy (Muscular Dystrophy), which are viewed as genetic diseases in modern medicine, are also virus-related diseases. Many neurological diseases of unknown cause or discussed as genetic diseases, such as Down's syndrome, Cri du chat syndrome, and muscular dystrophy, are nerve regeneration based on the administration of the antiviral agent according to the present invention. I have experienced many cases of improvement through the process. Through these repeated experiences, it was speculated that there are many diseases caused by viral infection among the diseases discussed as genetic diseases.

The present inventors speculate that dementia is also a virus-related disease. As the cause of developmental disorder and brain lesion disorder was assumed to be a central nervous system disease caused by a virus, and the symptoms improved when the virus was eradicated, dementia was assumed to be the same cause. It is thought that the antiviral agent according to the present invention will also play a large role in the prevention and treatment of dementia.

As such, based on the research and clinical experience so far, it is speculated that many diseases with unknown causes and many diseases thought to be genetic diseases will belong to viral diseases.

[Example]

1) For an in-vitro test for viral diseases, the antiviral extract according to the present invention was prepared several times in the following amount.

180g of maple syrup, 220g of tabasheer, 320g of Euiin powder, 120g of Manuka honey, 270g of xylitol powder, 120g of vitamin C powder, 50g of boswellia, 100g of myrrh powder, 20g of propolis is mixed with 50% ethanol 1:30 (Mixture 1: 50% ethanol 30) was mixed in a weight ratio and extracted for 3 to 12 hours at a temperature of 100 to 120 ° C in a pressure extractor to make an antiviral extract.

2) Antiviral drug pills according to the present invention were prepared several times at the following ratios for clinical trials and drug efficacy confirmation for viral diseases.

Maple syrup 10%, tabasheer 12%, uiiin powder 20% by weight, xylitol powder 22% by weight, vitamin C powder 7% by weight, frankincense extract powder 5% by weight, myrrh powder 10% by weight, propolis extract powder 2% by weight After making a mixed powder of, 12% by weight of Manuka honey was further mixed thereto to make a small freeze-dried pill having a diameter of 3.8mm, and then packaged in units of 4.8g. In order to obtain an extract of frankincense and propolis, frankincense and propolis are mixed with 50% ethanol and 1:30 (balm or propolis 1:50% ethanol 30) in a weight ratio, respectively, and the temperature is 100~120℃ in a pressure extractor. After extraction for 3 to 12 hours, the ethanol was evaporated for an appropriate time to remove the ethanol component, the residue was removed, and the mixture was dried and powdered.

<Antiviral test>

Influenza A virus (H1N1: influenza A virus), Human Rhinovirus A (HRV: nasal cold virus), Transmissible gastroenteritis virus (TGEV: Infectious gastroenteritis virus) and Encephalomyocarditis virus (EMCV: encephalomyocarditis virus) were used as test viruses, A test for measuring the antiviral activity of the antiviral agent according to the present invention was conducted according to ASTM E1052-11.

1.1. Host cell culture

MDCK, HeLa, ST, and Vero cells were cultured using a cell culture medium at 5% CO ₂ concentration, (36±2)°C conditions.

1.2. virus culture

1.2.1. Influenza A culture

After washing the MDCK cells monolayer cultured in a 75-cm² flask with PBS, 3mL of Influenza A dilution was inoculated. After infecting the virus for 60~90 minutes at 5% CO ₂ concentration and (33±2)℃ condition, add the virus culture medium and incubate the virus for (5~7) days until more than 90% of the host cells show cellular lesions. cultured. Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.

1.2.2. HRV culture

HeLa cells cultured as monolayers in a 75-cm² flask were washed with PBS, and then inoculated with 3 mL of HRV dilution. After infecting the virus for 60-90 minutes at a 5% CO ₂ concentration and (33±2)℃ condition, the virus culture medium was added and the virus was cultured for 3-7 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.

1.2.3. TGEV culture

After washing the monolayer-cultured ST cells in a 75-cm² flask with PBS, EMEM (w/o TPCK-treated trypsin) was added, and the cells were placed at 5% CO₂, (36 ± 2) °C for 3 hours. Thereafter, 3 mL of a TGEV dilution diluted with a virus culture medium (w/ TPCK-treated trypsin) was inoculated. After infecting the virus for 60-90 minutes at a 5% CO ₂ concentration and (33±2)℃ condition, the virus culture medium was added and the virus was cultured for 3 to 5 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.

1.2.4. EMCV culture

After washing the Vero cells monolayer cultured in a 75-cm² flask with PBS, 3 mL of EMCV dilution was inoculated. After infecting the virus for 60-90 minutes at a 5% CO ₂ concentration and (36±2)℃ condition, the virus culture medium was added and the virus was cultured for 1 to 4 days until more than 90% of the host cells showed cellular lesions. . Then, the culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the supernatant was filtered with 0.2 filter to separate the virus.

1.3. antiviral test

1.3.1. Cytotoxicity test

After mixing the virus culture medium with the test solution in a ratio of 1:9 (90% test solution), the virus culture medium was diluted 10-fold in steps. After the diluted test solution was treated at (36 ± 1) °C for 30 to 60 minutes, the cytotoxicity was observed visually through a microscope.

1.3.2. Cell culture control

The host cells were treated with a virus culture medium and used as a cell culture control.

1.3.3. virus control

The test virus was mixed in a virus culture medium in a ratio of 1:9 and treated at (22 ± 2) °C for 1 hour. This mixture was treated in the same manner as in the neutralization method (1.3.4.) of the virus test group, and then diluted 10-fold in the virus culture medium, and each dilution was inoculated into host cells.

1.3.4. virus test group

The test virus was mixed with the test solution in a ratio of 1:9 and treated at (22 ± 2) °C for 1 hour. As it was confirmed that the test solution induces cytotoxicity through a preliminary test, the test solution was neutralized using a gel filtration column according to ASTM E1482-12. After that, immediately after 10-fold serial dilution in the virus culture medium, each dilution was infected with the host cells.

1.4. verification test

1.4.1. sub-cytotoxicity

After treating the host cells with the highest concentration of the test solution that did not show cytotoxicity for 30 minutes, the cell monolayer was washed with PBS, and the virus was inoculated. After that, the virus was infected for 60-90 minutes at a 5% CO ₂ concentration, (33±2) ℃ condition (Influenza, HRV) or (36±2) ℃ condition (TGEV, EMCV) and 5% CO ₂ concentration, (33 Incubated for 3 to 10 days under ±2)℃ conditions (Influenza, HRV) or (36±2)℃ conditions (TGEV, EMCV).

1.4.2. neutralization test

The neutralized test solution and virus were mixed in equal amounts and reacted for (10-20) minutes, and then inoculated into host cells. After that, the virus was infected for 60-90 minutes at a 5% CO ₂ concentration, (33±2) ℃ condition (Influenza, HRV) or (36±2) ℃ condition (TGEV, EMCV) and 5% CO ₂ concentration, (33 Incubated for 3 to 10 days under ±2)℃ conditions (Influenza, HRV) or (36±2)℃ conditions (TGEV, EMCV).

1.5. Virus Recovery

Step-dilute each solution 10 times after the reaction, and treat each step-by-step dilution in 8 wells of 100 cells in a 96-well plate, 5% CO ₂ concentration, (33±2)℃ condition (Influenza, HRV) or (36±2)°C conditions (TGEV, EMCV) for 3 to 10 days.

1.5.2. dyeing conditions

Cells were treated with a staining reagent of 25% methyl alcohol (v/v) and 0.5% crystal violet (w/v) and stained at (22 ± 2) °C for 10 minutes.

1.5.3. Observe the results

The number of wells stained with crystal violet was counted and the titer was calculated by the Spearman-Karber method. Virus titer was calculated according to Equation 1 in Section 1.6.1., and the reduction rate was determined according to Equation 2 in Section 1.6.2.

1.6. Calculate the result

1.6.1. Virus titer calculation

[Formula for calculating virus titer]

L = X ₀ -(d/2) + dx Σ(r _i /n _i )

L: Log ₁₀ TCID ₅₀ titer

X ₀ : Log ₁₀ of the reciprocal of the lowest dilution at which all test inocula are positive

d : Log ₁₀ of the dilution factor(that is, the difference between the log dilution intervals)

n _i : Number of test inocula used at each individual dilution

r _i : Number of positive test inocula (out of n _i )

Σ(r _i /n _i ) : Sum of the proportion tests beginning at the lowest dilution showing 100% positive result

1.6.2. Calculation of reduction rate [Log reduction (LR)]

[Log reduction formula]

LR = ML _U - ML _T

ML _U = Mean of the titers recovered from the virus control specimen(untreated)

ML _T = Mean of the titers recovered from virucidal test specimen(treated)

However, log values are indicated up to 2 decimal places.

1.7. Test completion conditions

1.7.1. Cytotoxicity test

Cytotoxicity of host cells by the test solution should not be observed. If the test solution directly induces cytotoxicity, it should be neutralized using a gel-filtration column.

1.7.2. cytotoxicity test

Although cytotoxicity by the test solution was not observed through visual observation, since the test solution can increase or decrease the virus infectivity of cells, it is necessary to check whether or not cytotoxicity is present. When the virus titer was lower than that of the control by (45 ± 5) % or more, the corresponding dilution factor was excluded from the reduction rate calculation.

1.7.3. neutralization test

After the test solution is neutralized at the time when the reaction between the test solution and the virus is finished, the neutralization should be verified. If the recovery of the virus is observed to be lower than (80 ± 5) % compared to the control group, sufficient neutralization has not been achieved, so an appropriate neutralization step must be performed using a method such as a gel-filteration column.

2. Results

2.1. Cytotoxicity of the test solution

After mixing the virus culture medium with the test solution in a ratio of 1:9 (90% test solution), it was confirmed that cytotoxicity was induced for all host cells. After neutralizing the test solution using filtration columns, it was used for the test. The neutralized test solution showed cytotoxicity up to 90% concentration (Table 1).

Cytotoxicity test result
cell host

The highest dilution that does not show toxicity (concentration of test solution) MDCK cells 10 ^-2 (9%) Hela cells 10 ^-2 (9%) ST cells 10 ^-2 (9%) Vero cells 10 ^-2 (9%)

2.2. Antiviral test results

Antiviral test results are shown in Tables 1 and 2 below.

Antiviral test result (L) (unit: log ₁₀ TCID ₅₀ /mL)
virus

Virus control (after 1 hour)
Test group (after 1 hour)
Influenza A

5.63
< 2.50
HRV
7.88
3.25
TGEV

6.75
4.88
EMCV

8.63
8.50

Virus Reduction Rate (LR)
virus

LR
Influenza A

>3.13

HRV
4.63

TGEV

1.87

EMCV

0.13

If LR (Log reduction) is 1 or more, the virus reduction percentage (% redution) is 90% or more, If LR (Log reduction) is 2 or more, the virus reduction percentage (% redution) is 99% or more, LR (Log reduction) is If 3 or more, the virus reduction percentage (% redution) is 99.9% or more, if LR (Log reduction) is 4 or more, the virus reduction percentage (% redution) is 99.99% or more, and if LR (Log reduction) is 5 or more, the virus reduction percentage (% redution) is more than 99.999%. As a result of the test, it can be seen that a significant virus reduction rate was obtained for all kinds of test viruses, and it can be seen that the virus reduction percentage was more than 99.9% in some cases.

The results of the blast toxicity test and the neutralization test are shown in Tables 4 and 5 below.

Results of cytotoxicity test (unit: log ₁₀ TCID ₅₀ /mL)
virus

control
test group
result judgment
Influenza A

5.63
5.38
Lack of Interference
HRV

7.50
7.13
Lack of Interference
TGEV

6.75
6.50
Lack of Interference
EMCV

8.38
8.38
Lack of Interference

Neutralization test result (unit: log ₁₀ TCID ₅₀ /mL)
virus

control
test group
result judgment
Influenza A

5.50
5.13
successful neutralization
HRV

7.13
6.88
successful neutralization
TGEV

6.63
6.38
successful neutralization
EMCV

8.50
8.75
successful neutralization

2.2.1 Efficacy of Influenza A Antiviral Test

The titer of the virus control was 5.63 log ₁₀ TCID ₅₀ /mL, and the titer of the test group was < 2.50 log ₁₀ TCID ₅₀ /mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).

2.2.2 Efficacy of HRV antiviral test

The titer of the virus control was 7.88 log ₁₀ TCID ₅₀ /mL, and the titer of the test group was 3.25 log ₁₀ TCID ₅₀ /mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).

2.2.3. Efficacy of TGEV antiviral test

The titer of the virus control was 6.75 log ₁₀ TCID ₅₀ /mL, and the titer of the test group was 4.88 log 10 TCID50/mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).

2.2.4. Efficacy of EMCV antiviral test

The titer of the virus control was 8.63 log ₁₀ TCID ₅₀ /mL, and the titer of the test group was 8.50 log ₁₀ TCID ₅₀ /mL (Table 2).

No titer was observed in the cell culture control, no cytotoxicity and cytotoxicity of the test solution (9%) were observed, and the neutralization of the sample was confirmed in the neutralizing control, thus proving the effectiveness of this test (Table 4, Table 4). 5).

3. Conclusion

Virus reduction rates (log reduction) of Influenza A, HRV, TGEV and EMCV for the antiviral agent test solution of the present invention under these test conditions were >3.13, 4.63, 1.87, and 0.13, respectively (Table 3). Therefore, the present invention confirmed that there is antiviral activity against these viruses.

<Clinical trial>

<Measurement of effect on hepatitis B>

7 male and 3 female hepatitis B patients with GOT in the range of 50 to 60 U/ml were given the antiviral agent according to the present invention 2 sachets at a time for 3 months at t.i.d. As a result of GOT measurement, one male hepatitis patient Except for , GOT measurement results of 32 ~ 38U/ml, which are all within the normal range, were obtained for the remaining 9 patients.

<Measurement of effect on influenza A virus>

For 4 influenza A patients complaining of high fever, chills, headache, muscle pain, etc., 3 packets of the antiviral agent according to the present invention were administered t.i.d. for 5 days. It was confirmed that the body temperature of the three persons returned to normal body temperature within 3 days of taking the drug, and the high fever, chills, and muscle pain disappeared.

<Measurement of effect on rhinovirus>

5 females and 5 males of nasal cold (rhinovirus infection) patients were instructed to take the antiviral agent according to the present invention, one pack each, t.i.d. for 5 days. After 5 days, it was confirmed that the symptoms of runny nose as well as runny nose completely disappeared in 4 women and 3 men, and the symptoms of runny nose were significantly alleviated in the remaining 3 patients.

<Measurement of effect on adenovirus>

3 female and 3 male patients with sore throat (adenovirus infection) were instructed to take 2 packets of the antiviral agent according to the present invention b.i.d. for 4 days. After 4 days, it was confirmed that the symptoms of the common cold disappeared in 3 patients, and the symptoms of a sore throat, such as neck pain, were remarkably alleviated in the remaining 3 patients.

<Measurement of effect on herpes zoster>

For 3 patients who had been diagnosed with herpes zoster for more than 1 year (hereafter, long-term treatment patient group), and 5 patients who had been diagnosed with herpes zoster for less than 1 month (short-term patient group), for the long-term treatment patient group, The antiviral agent according to the present invention was to be taken for 2 months at t.i.d, 2 sachets each, and 1 sachet per b.i.d for 1 month for the short-term treatment patient group. In the long-term treatment group, it was observed that after 2 months of taking, the pain disappeared and herpes zoster completely disappeared in 2 patients. In the short-term treatment group, after 1 month of taking, 4 patients with pain disappeared and herpes zoster was no longer observed.

<Measurement of effect on psoriasis>

After being diagnosed with psoriasis, for 3 male and 4 female patients who had not been treated for more than 1 year, the antiviral agent according to the present invention was administered t.i.d. for 4 months, and the condition was observed after 4 months. did. After 4 months, no scales or erythema were observed in 2 male and 2 female patients. In the remaining patients, it was confirmed that the range of scale and erythema was reduced to less than 1/3 compared to before administration.

<Measurement of effect on atopic dermatitis>

For 5 patients with atopic dermatitis accompanied by pruritus on the arms and 5 patients with atopic dermatitis accompanied by pruritus on the legs, the antiviral agent according to the present invention was administered t.i.d. 2 sachets each for the first 1 month The condition was observed while additionally taking 1 pouch each t.i.d for 3 months after 1 month. After taking the first month, pruritus disappeared and inflammation was relieved in 9 of 10 patients. After 3 months of additional dosing, inflammation was no longer observed in 4 patients, and in 3 patients, the extent of inflammation was reduced to less than 1/4 compared to before administration. There was no pruritus remaining after 3 months of additional use.

<Measurement of effect on cervical myofascial pain syndrome)

10 patients with cervical myofascial pain who feel neck pain even without movement were selected, and 5 patients (M1-M5) were given the pill according to the <Example> of the present invention, 1 packet once for 28 days, 3 times a day, The other 5 patients (m1-m5) were given Tylenol 650 mg, an 8-hour sustained-release drug, which is commonly prescribed for cervical myofascial pain syndrome, as a <comparative example>, and the effect was measured by taking one tablet three times a day for 28 days. .

After 28 days of taking, 5 points were given if no pain was felt even when moving, 3 points if no pain was felt when not moving but pain was felt when moving, and 1 point if pain was felt even when not moving.

The measurement results are shown in Table 6 below.

<Example> Patients taking

<Comparative example> Patients taking

M1

M2
M3
M4
M5

m1
m2
m3
m4
m5
3

3
One
5
3
3
One
3
One
3

From the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.

<Measurement of effect on chronic plantar fasciitis)

Ten patients with chronic plantar fasciitis who felt pain in their feet even without walking were selected, and 5 patients (M1-M5) were given the pills according to <Example> of the present invention, 2 capsules, 3 times a day for 28 days, The other 5 patients (m1-m5) were given Tylenol 650 mg, an 8-hour sustained-release drug, which is a commonly prescribed pain reliever for chronic plantar fasciitis, once for 28 days, 3 times a day, and the effect was measured.

After 28 days of taking, 5 points were given if no pain was felt even when moving, 3 points if no pain was felt when not moving but pain was felt when moving, and 1 point if pain was felt even when not moving.

The measurement results are shown in Table 7 below.

<Example> Patients taking

<Comparative example> Patients taking

M1

M2
M3
M4
M5

m1
m2
m3
m4
m5
3

5
3
One
3
3
One
3
One
3

From the above measurement results, it can be seen that the pain improvement degree of the patient taking the pill according to the embodiment of the present invention is superior to the pain improvement degree of the patient taking the pill according to the comparative example.

<Measurement of effect on periodontal disease>

Twenty patients with gingivitis that persisted for more than one year were divided into groups A and B of 10 each, and group A was According to the present invention, the <Example> according to the present invention was taken for 3 months by tid, one package at a time, and for group B, as a <Comparative example>, dentamine capsules (Ilyang Pharm), a commercially available gingivitis treatment, 1 capsule 3 times a day After taking each tooth for 3 months, select one tooth with the most severe gingivitis and partition it into buccal and lingual surfaces. According to Loe &Silness's rating criteria, normal gingiva is 0 points, mild inflammation and color change, or mild edema. If there is no bleeding by the periodontal probe, 1 point, severe inflammation, redness, edema, and gingival color change, as well as bleeding due to mild irritation with the periodontal probe, 2 points, severe inflammation, redness, edema, and ulcer. In case of spontaneous bleeding, it was evaluated as 3 points, and the buccal and lingual gingivitis index for each tooth of each group was calculated before taking, 1 month after taking, 2 months after taking, and 3 months after taking it, and the average score was calculated. The results are shown in Table 8 below.

just before taking
(mean ± standard deviation) 1 month after taking
(mean ± standard deviation) 2 months after taking
(mean ± standard deviation) 3 months after taking
(mean ± standard deviation)
Improvement (%)
Group A-
Example


1.83±0.31



1.71±0.20


1.35±0.21


0.89±0.30


51.37%

Group B-
comparative example
(Dentamine Capsule)



1.78±0.38

1.70±0.33


1.48±0.38


1.35±0.41


24.15%

The improvement rate (%) was calculated by the following formula using the average value of the Witch Gingivitis Index just before taking and the average value after 3 months of taking it.

Improvement rate (%) = (Gingivitis index just before taking - Gingivitis index after 3 months of taking) / Gingivitis index just before taking x 100

As can be seen in the table above, in both Examples and Comparative Examples, the gingivitis index showed a tendency to gradually decrease as the period of administration increased. However, the rate of change was larger in the example than in the comparative example. In particular, it was confirmed that the improvement rate after taking for 3 months was almost twice as high in the example of the present invention as compared to the comparative example.

<Measurement of effect on chronic cystitis>

1) Antiviral agent according to the present invention for 20 patients with symptoms of nocturia and urgency, and the frequency of urination in the last 1 month ranged from 10 to 16 times a day among women aged 40 to 70 who were diagnosed with chronic cystitis at the hospital The effect of the present invention was evaluated by making a urination diary to be taken 3 times a day, 1 sachet at a time.

As shown in Table 9, the average daily urination frequency, the average nocturia frequency, and the average daily urgency frequency were all significantly improved.

<For 3 times a day, 1 sachet at a time>
just before taking
3 days average

4 weeks after taking
3 days average

8 weeks after taking
3 days average
12 weeks after taking
3 days average
Average number of urinations/day

Episode 14.2
Episode 12.1
11.0 episodes
9.8 episodes
Average nocturia/day

3.2 episodes
2.7 episodes
2.2 episodes
1.5 times
Average number of urgency/day

2.9 episodes
2.3 episodes
2.1 episodes
1.0 episodes

2) Antiviral agent according to the present invention for 20 patients with symptoms of nocturia and urgency, with the frequency of urination ranging from 12 to 18 times a day for the past 1 month among women aged 40 to 70 who were diagnosed with chronic cystitis at the hospital The effect of the present invention was evaluated by making a urination diary to be taken 3 times a day, 2 packs at a time.

As shown in Table 10, the average daily urination frequency, the average nocturia frequency, and the daily average urgency frequency were all significantly improved.

As a result of this clinical example, it was confirmed that a significant improvement effect appeared when the dose was increased in patients with relatively severe cystitis.

<Take 2 sachets at a time, 3 times a day>
just before taking
3 days average

4 weeks after taking
3 days average

8 weeks after taking
3 days average
12 weeks after taking
3 days average
Average number of urinations/day

Episode 15.8
13.0 episodes
10.9 episodes
8.8 episodes
Average nocturia/day

3.3 episodes
2.5 reps
2.0 episodes
1.5 times
Average urgency/day

3.0 episodes
2.3 episodes
Episode 1.7
0.8 reps

<Measurement of effect on hypertension>

Five hypertensive male patients with fasting systolic/diastolic blood pressures of (M1)155mmHg/125mmHg, (M2)149mmHg/120mmHg, (M3)164mmHg/128mmHg, (M4)158mmHg/122mmHg, (M5)148mmHg/115mmHg, respectively, and fasting systolic blood pressure /The present invention was conducted on 5 hypertensive female patients with diastolic blood pressure of (W1)152mmHg/115mmHg, (W2)148mmHg/119mmHg, (W3)165mmHg/126mmHg, (W4)157mmHg/121mmHg, (W5)149mmHg/121mmHg, respectively. Antiviral drugs were taken for 3 months each t.i.d., and fasting blood pressure was measured again after 3 months. The measurement results were (M1)135mmHg/95mmHg, (M2)129mmHg/98mmHg, (M3)134mmHg/90mmHg, (M4)145mmHg/111mmHg, (M5)140mmHg/100mmHg for 5 male patients, respectively, and 5 female patients. (W1)132mmHg/85mmHg, (W2)128mmHg/90mmHg, (W3)167mmHg/130mmHg, (W4)127mmHg/89mmHg, (W5)139mmHg/109mmHg for each person. Although there were individual differences in blood pressure drop in 9 patients, blood pressure dropped after taking the drug compared to before taking it. In many hypertensive patients, it has been determined that viral infection raises blood pressure by causing inflammation in certain parts of the body, such as the walls of blood vessels.

<Measurement of effect on diabetes>

Diabetes (P1) 134 mg/dl, (P2) 139 mg/dl, (P3) 132 mg/dl, (P4) 131 mg/dl, (P5) 128 mg/dl measured 3 times in the fasting state for 8 hours (P5) Type 2 diabetes) For 5 patients, 1 packet of the antiviral agent according to the present invention was administered t.i.d. for 3 months, and blood glucose was measured. As a result, the average blood glucose measured three times was (P1) 133 mg/dl, (P2) 139 mg/dl, (P3) 130 mg/dl, (P4) 132 mg/dl, and (P5) 125 mg/dl, respectively, and there was no significant change. . For these patients, the antiviral agent according to the present invention was again taken for 3 months at a t.i.d., one pack each, and the diabetes test was re-executed 6 months after the first dose. As a result, the average blood glucose measured three times ( P1) 120 mg/dl, (P2) 125 mg/dl, (P3) 119 mg/dl, (P4) 117 mg/dl, and (P5) 124 mg/dl were obtained. As a result of the analysis, it was a result of bringing about a decrease in blood sugar of about 10% except for one patient. Diabetes was expected to be a disease caused by a virus causing inflammation in the beta cells of the pancreas and raising blood sugar.

<Clinical example for individual patients>

[Clinical trial 1] Hepatitis B (50 years old, male)

A 50-year-old male patient complained of fatigue and anemia due to liver inflammation caused by the hepatitis B virus. When infected with a virus, our body triggers an immune response to eliminate it, which destroys infected liver cells, causing inflammation in the liver and feeling tired. In some cases, symptoms of anemia may appear. This patient was given 1 unit (4.8 g) of the antiviral agent according to an embodiment of the present invention 3 times a day for 3 weeks, and liver function tests were performed. As a result, the levels of GOT and GPT increased rapidly, but they did not complain of worsening symptoms or fatigue, and the symptoms of anemia disappeared. This is because hepatitis B virus-infected hepatocytes are suddenly exposed to the antiviral agent of the present invention, and in the process of eradicating the virus, the virus-infected hepatocytes are also destroyed, and GOT and GPT in the hepatocytes are released into the blood. After that, for 11 months, the antiviral agent according to the embodiment of the present invention was appropriately added or decreased to continue taking it. After 11 months, the hepatitis B virus marker test was performed on this patient. As a result, the hepatitis B virus surface antigen (s-antigen) was not detected at all.

[Clinical Trial 2] Herpes zoster (6 years old, female)

A six-year-old girl whom the inventor met in Beijing was suffering from herpes zoster. Strangely, this girl said that she had no symptoms when she was in Beijing, but showed symptoms two days later when she returned to her hometown. The antiviral agent according to an embodiment of the present invention was taken by 0.5 units in the morning and evening twice a day for 2 months. After that, I went back to my hometown, and no herpes zoster rash was observed after 2 days, 7 days, or 10 days after that. Since then, there has been no recurrence of herpes zoster. have.

[Clinical Trial 3] Herpes zoster (male, 84 years old)

An 84-year-old man, after treatment for herpes zoster at a dermatologist, suffered from back, shoulder, and rib pain that became so severe that he could not sleep at night. Herpes zoster is a disease that occurs when the chickenpox-herpes zoster virus causes chickenpox in childhood and then remains dormant in the body and then reactivates. Viruses remaining in the body move along nerves and dormant in ganglia, and when immunity is weakened, painful inflammation occurs in the skin. 2 units (4.8g x 2) of the antiviral agent according to an embodiment of the present invention were taken twice a day for 3 days, and then 1 unit (4.8g) was taken three times a day for 7 days more. This patient stated that the pain had completely disappeared after 10 days had elapsed, and herpes zoster was no longer observed except for some traces of herpes zoster.

[Clinical Trial 4] Herpes zoster (36 years old, male)

A 36-year-old, strong male patient. I came to buy a pain reliever because I have herpes zoster and I can't sleep because of the pain, even though I am taking prescription drugs. Instead of an analgesic band, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, three times a day for 3 days. The patient stated that after 3 days, signs of herpes zoster remained, but the pain had completely disappeared. After that, it was confirmed with the naked eye that herpes completely disappeared by further taking the same amount for 10 days. In order to completely eliminate the latent chickenpox-herpes zoster virus, the antiviral agent according to the embodiment of the present invention was further taken for 4 months.

[Clinical Trial 5] Herpes zoster (60 years old, female)

A few years ago, a patient suffered from herpes zoster for nearly a year. I have been prescribed gabapentin, an antiviral drug for herpes zoster, at the hospital saying the same area is tingling again. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 3 days. The next day, the pain disappeared immediately, and I decided not to take the hospital prescription medication. In order to completely eliminate the varicella-zoster virus dormant in nerve cells, the antiviral agent according to the embodiment of the present invention was further taken for 6 months.

[Clinical trial 6] Influenza (63 years old, male)

It was a patient who was prescribed Tamiflu for 1 week due to symptoms of H1N1 flu. Since the symptom improvement due to Tamiflu was insignificant, 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for one week. After 1 week, symptom improvement was evident, and the dose was increased by 1 unit each three times a day for 1 week. Two weeks later, the patient stated that the H1N1 flu symptoms had completely disappeared.

[Clinical Trial 7] Influenza (56 years old, male)

It was an influenza patient who complained of high fever and general pain due to influenza B virus infection. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 3 days. This patient stated that his symptoms improved significantly after 3 days. After that, 1 unit was taken twice a day for 1 week. This patient stated that the symptoms completely disappeared 10 days after starting the treatment.

[Clinical trial 8] Nasal cold (45 years old, female)

It was a female patient who said that if she usually catches a cold once, it doesn't get better and lasts a long time. The patient was infected with Rhinovirus. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 days. This patient stated that the cold symptoms completely disappeared within 3 days.

[Clinical trial 9] Nasal cold (21 years old, female)

It was a female patient who was about to be tested. I found a cold medicine that doesn't make me sleepy. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 6 days. After taking it for 2 days, he complained that his runny nose got worse, but he continued to take it. This patient stated that from the 4th day, the nasal passages were pierced, the head became clear, and the cold symptoms completely disappeared after taking it for 6 days.

[Clinical trial 10] Sore throat (48 years old, male)

It was a male patient with a sore throat. The patient was infected with adenovirus. Although one unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 3 days, the cold symptoms did not improve because the air conditioner worked in an office with a low temperature. The antiviral agent according to an embodiment of the present invention was increased by 2 units three times a day to be taken for 3 more days. This patient stated that the symptoms of a cold in the throat disappeared after 3 days.

[Clinical Trial 11] Sore throat (40 years old, female)

It was a 40-year-old female patient whose life changed day and night. The patient was infected with adenovirus. He visited the hospital several times due to a continuous sore throat, and he continued to receive Ringer every time he visited the hospital, but he was dissatisfied because his symptoms did not improve. One unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 days. This patient stated that from the second day, it was much easier to get up in the morning, the cold symptoms improved a lot, and the cold symptoms completely disappeared within a week.

[Clinical trial 12] Chronic sputum (73 years old, male)

This 73-year-old male patient has been taking hospital prescription drugs for more than three years because his sputum is still boiling. The antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, three times a day for 7 days. As a result, the amount of sputum was significantly reduced. This patient was instructed to take 1 unit twice a day for an additional 3 months. After an additional 3 months of dosing, the patient stated that she no longer had sputum. Most of the chronic diseases occurring in the mucous membranes are the result of prescribing with a high possibility of viral diseases.

[Clinical trial 13 ] Psoriasis (38 years old, male)

This patient had been diagnosed with psoriasis at the hospital, where skin lesions began 8 years ago, and he has been receiving continuous treatment. He had severe erythematous skin lesions characteristic of psoriasis evenly over the entire skin. Initially, one unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 3 months. After 1-2 weeks of taking, skin lesions began to grow all over the body, and after 12 weeks, there was a lot of improvement. After 6 months, scales or erythema were no longer observed with the naked eye. Psoriasis is an erythematous skin lesion covered with silvery-white scales with clear boundaries. Once onset, it is a representative chronic skin disease that is likely to recur throughout life. The cause is unknown.

[Clinical trial 14 ] Psoriasis (31 years old, female)

Skin lesions started from 20 years ago before management with the antiviral agent according to an embodiment of the present invention, and each hospital was diagnosed with psoriasis. He had severe erythematous skin lesions characteristic of psoriasis evenly over the entire skin. The antiviral agent according to an embodiment of the present invention was taken for 3 months while appropriately adjusting the dosage. Within 1-2 weeks of taking, the symptoms worsened, and skin lesions appeared all over the body, and erythema and scales gradually disappeared after 3-4 weeks. As a result of taking the dose of the antiviral agent according to an embodiment of the present invention appropriately for 24 months, erythema or scale was no longer observed with the naked eye. It was determined that the antiviral agent according to an embodiment of the present invention was the result of erasing all the viruses that cause psoriasis.

[Clinical trial 15 ] Psoriasis (55 years old, male)

This is a patient who has been pointed out by the barber for several years every time a haircut is done that a well-demarcated erythematous skin lesion that is covered with scales from the scalp on the back of the head to the border of the back of the neck spreads about half the size of the palm of the hand. It was judged to be psoriasis, and 1 unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 1 month. After 1 month, a marked decrease in borderline was observed. After 1 month, the amount was increased and the antiviral agent according to an embodiment of the present invention was taken by 1 unit three times a day for 3 more months. After 3 months, the erythema had almost disappeared and became almost indistinguishable from the surrounding skin color. In order to cure the virus causing psoriasis, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, twice a day for 3 more months.

[Clinical trial 16] Atopic dermatitis (36 years old, male)

I had atopic dermatitis since I was a child, but there were no major symptoms. From 3 years ago, symptoms appeared on the forehead, wrists, and back of the neck, and suddenly started to get worse from the reverse of 1 year, and now the whole body is a patient with severe symptoms. He was diagnosed with atopic dermatitis at the hospital. The skin is very itchy and dry, pulling, cracking in severe areas, bleeding, and the symptoms are so severe that I can't sleep, so I get warm water in the bathtub every two days and pour out the hot water little by little to keep it from getting cold. said to have slept His atopy was so severe that he had already retired from his job. For the first 2 months, 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day, and then 1 unit was taken three times a day for an additional 7 months. The symptoms seemed to get worse between 7-14 days after the first dose, but the treatment was continued without stopping. After 9 months, no atopic symptoms could be observed in this patient's skin, and the patient stated that he no longer felt itching.

[Clinical trial 17] Atopic dermatitis (48 years old, male)

This man was a patient with severe atopic dermatitis on the face. The patient took antihistamines and immunosuppressants prescribed by a dermatologist, but his symptoms did not improve. This patient with a red and swollen face was instructed to take 2 units of the antiviral agent according to an embodiment of the present invention three times a day for 7 days. After 7 days, the red, swollen skin calmed down and the color of the face returned to normal. After confirming the above effect, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time three times a day for 6 months. After starting the application of the present invention, the symptoms of atopic dermatitis in which the face becomes red and swollen did not occur anymore, and it was visually confirmed that other symptoms of atopic dermatitis disappeared after taking it for 6 months.

[Clinical trial 18] Atopic dermatitis (17 years old, female)

This patient, a 17-year-old high school girl, had atopic dermatitis on the back of the knee and thigh. 2 units of the antiviral agent according to an embodiment of the present invention were taken three times a day for 14 days. At first, as expected, the symptoms worsened, but gradually improved. Thereafter, in order to cure the virus causing atopic dermatitis, the antiviral agent according to an embodiment of the present invention was taken 1 unit at a time, twice a day for another 6 months. After 6 months of taking, no symptoms of atopic dermatitis were observed in the back of the knee and thigh as well as in other areas.

[Clinical trial 19] Vitiligo (34 years old, male)

In this patient, the symptoms of vitiligo were particularly severe on the face, hands, and wrists, and were spread evenly throughout the body, making it difficult to lead a normal social life. In particular, some of the eyelashes on the eyelids where vitiligo had progressed had turned white. The antiviral agent according to an embodiment of the present invention was appropriately adjusted and taken for 24 months. As a result of visual observation after 24 months, most of the symptoms of vitiligo (white spots) disappeared from the skin, but the white eyebrows remained. Although the exact cause is unknown, vitiligo is an acquired depigmentation disease in which white spots of various sizes appear on the skin due to the destruction of melanocytes. It is also a disease that is difficult to completely cure, although various methods are tried to treat it. If you look at the symptoms of vitiligo, the skin around the skin with white spots due to discoloration secretes a lot of melanin, which is darker than normal skin. Although it is not a typical form of viral inflammation, it was speculated that melanocytes are a skin disease caused by infection with a virus sensitive to melanocytes based on clinical experience. When melanocytes die due to virus infection, they cannot secrete melanin pigment and cause vitiligo, but until they die, it is presumed that the surrounding skin turns black by secreting more melanin pigment due to inflammatory stimulation by the virus. Therefore, the healing process of vitiligo is to first eradicate the virus that is the cause. It is to create and maintain a skin environment for melanocytes to settle thereafter. Then, when the healing process is almost finished, the white spots become normal flesh color, and at the same time, the surrounding dark skin returns to the flesh color and is healed. The treatment of vitiligo requires a long time of 12-24 months in experience, and the improvement effect does not appear at the initial stage, but it is a disease that begins to appear when the healing is almost complete.

[Clinical trial 20] Chronic rhinitis (40 years old, female)

As a 40-year-old woman, the mucous membrane of the nose was always swollen due to chronic rhinitis, so it was difficult to sleep unless a humidifier was turned on while sleeping. Antiviral agents according to an embodiment of the present invention were taken twice a day for 12 weeks, each 1 unit. From the 3rd week onward, breathing became easier, the nasal mucosa was noticeably reduced, and the nose began to feel very comfortable. After 12 weeks, the patient stated that he no longer felt the previous chronic rhinitis. The sinuses and airways are areas that come into contact with the outside air and are easily exposed to viruses and bacteria, so they are easy to get infected. Diseases caused by bacterial infection have been improved with the development of antibiotics, and, with the exception of tuberculosis, it is rare to progress to chronic diseases. However, in the case of viral infection, the development of antiviral agents that can kill the virus is insignificant and it is difficult to obtain an appropriate treatment, so it causes diseases such as chronic rhinitis, asthma, and tonsillitis. At this time, if the antiviral agent according to an embodiment of the present invention is taken, the virus that infects the sinuses or airways and causes inflammation is eliminated, and inflammation is reduced, thereby improving chronic rhinitis, asthma, and tonsil hypertrophy.

[Clinical trial 21] Sore throat (60 years old, female)

This patient had an uncomfortable and painful condition that continued for more than 6 months as if her neck was constantly tightened and stuck. I also checked for lumps in the neck, but there was no or no, and even after visiting the otolaryngologist for 2 months, there was no improvement. Accordingly, each 1 unit of the antiviral agent according to an embodiment of the present invention was taken three times a day for 7 days. After 7 days, the patient stated that the uncomfortable symptoms of the neck disappeared and that he was able to sleep comfortably. It was determined that the possibility of a viral infection of the throat mucosa was very high.

[Clinical trial 22] Chronic gastritis (54 years old, female)

This patient is a female pharmacist who has suffered from indigestion and congestion for a long time due to chronic gastritis. One unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that the symptoms of indigestion after eating disappeared after 2 weeks of taking the drug, and the symptoms of eating and sieving were no longer there. The gastric mucosa is a site where food enters directly from the outside, and like the nasal mucosa and airways, it is vulnerable to virus invasion. Therefore, when gastrointestinal diseases such as gastric atony, chronic gastritis, and gastric ulcer persist repeatedly without being cured with malignant treatment, it is necessary to suspect a viral infection. It is good to take the antiviral agent according to the embodiment of the present invention, such as chronic gastritis and gastric ulcer, which is not improved well even with gastric acid secretion inhibitors and antibiotics, and repeated gastric atony that does not improve well with gastrointestinal motility regulators. A number of clinical cases were obtained.

[Clinical trial 23] Allergy (55 months, male)

This patient was a 55-month-old boy. I have suffered a lot of food allergies from birth (apple peel, peaches, plums, fruits, shrimp, crustaceans, shellfish, eggs, nuts, etc.) appeared frequently. In addition, allergic (allergic) runny nose rhinitis persists and does not heal well when caught with a cold, and the eyes are always red due to frequent rubbing of the eyes due to allergic conjunctivitis. One unit of the antiviral agent according to an embodiment of the present invention was ground with a blender and mixed with yogurt, and then taken twice a day for 4 weeks. After 3 days of eating, it was possible to observe with the naked eye that the inflamed yellow runny nose changed to a clear runny nose, and the itching was reduced, so that the eyes did not rub, and the redness disappeared. Currently, allergy is known as a viral disease.

[Clinical trial 24] fibromyalgia (59 years old, female)

This patient was a chronic pain patient who complained of pain in the back, shoulder, arm, and leg, and complaining that there was no pain in the whole body. It was said that in the evening, it was hard and turned into green onion kimchi. One unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that from the 3rd day of taking, the body became lighter and the pain began to disappear, and from that moment on, there was no numbness or pain at all. This patient was suspected to have been infected with the virus in several parts of his body.

[Clinical trial 25] Chronic finger pain (58 years old, male)

One month ago, the first joint of the right thumb was bitten by a person and suture treatment was continued, but there was no suppuration and stabbing pain occurred, and the wrist and shoulder also suffered from severe muscle pain. Even 8 years ago, the same site was bitten by the same person and 80 stitches of suture treatment were performed. It was judged that it was a viral infection if there was no suppuration even though the pain continued for 1 month, and 1 unit of the antiviral agent according to an embodiment of the present invention was taken twice a day for 4 weeks. This patient stated that after 4 weeks the pain and myalgia had completely disappeared. Even after the pain and muscle pain disappeared, they were given the same dose for another 5 months to cure the virus.

[Clinical trial 26] Hypertension (53 years old, male)

This patient is a 53-year-old male patient. He usually has high blood pressure, but he complained that if he took blood pressure medication, his blood pressure dropped too much and he became unstable and had dizziness. This patient was instructed to take 1 unit of the antiviral agent according to the present invention twice a day for 3 months. After 3 months, the measured blood pressure dropped to around 121 mmHg in systolic blood pressure and 81 mmHg in diastolic blood pressure without taking blood pressure medication. Hypertension is a typical lifestyle-related disease that is caused by stimulant food, obesity, lack of exercise, and excessive stress. Although the present inventors did not initially think of hypertension as a viral disease, through these clinical cases in which blood pressure was controlled by taking the antiviral agent according to the present invention, viral infection can cause inflammation in a specific part of the body and raise blood pressure. was judged to be there.

[Clinical trial 27] Type 1 diabetes (42 years old, female)

This patient was diabetic and had severe foot pain. When I woke up every morning, it hurt so badly that I was stabbed in the soles of my feet with dozens of needles, so I couldn't put my feet on the floor right away. The diabetes of this patient was type 1 diabetes, which was developed after severe acute pancreatitis. At that time, even when insulin was injected in the morning and evening, the pre-meal blood sugar did not fall below 200 mg/dℓ, and the blood sugar rose higher 2 hours after a meal. Also, I was so thirsty that my tongue cracked, and the cold water wasn't cool, so I had to freeze the beer in the freezer or chew on ice to quench my thirst. The patient was not allowed to drink cold water, only water that was warmer than body temperature, and spicy food was also prohibited. After one week of control, the thirst disappeared and blood sugar began to stabilize. This means that cold stimulation causes excitability of the sympathetic nervous system, thereby breaking out of the vicious cycle of continuously raising blood sugar and causing thirst. Thereafter, the antiviral agent according to an embodiment of the present invention was appropriately taken (2 units twice a day for 3 months), and the insulin injection amount was reduced to 5 units only in the morning. This patient stated that the pain in the foot disappeared while taking the antiviral agent according to an embodiment of the present invention, and it was observed that the inflammation of the foot was also gradually reduced. Through this patient, it was confirmed that even with type 1 diabetes, the insulin injection amount could be reduced and symptoms improved. This was determined to be because the antiviral agent according to an embodiment of the present invention eradicated the virus causing inflammation in the beta cells of the pancreas. The decrease in insulin dose is regarded as evidence that the beta cells of the pancreas are regenerated and active. Diabetes, like high blood pressure, is a typical lifestyle disease, and it is a typical disease caused by stimulant food, obesity, lack of exercise, and excessive stress. Although the present inventor did not initially think of diabetes as a viral disease, while experiencing clinical cases in which blood sugar was controlled by taking the antiviral agent according to an embodiment of the present invention, the virus caused inflammation in a specific part of the body. It was diagnosed as a disease that raises blood sugar.

[Clinical trial 28] Infertility (31 years old, female)

this patient It was a case of taking a year off from work to get treatment for infertility and wanting to receive infertility treatment in earnest. However, in reality, her physical strength was so weak that even light daily life was difficult. In the case of female infertility, if there is no specific cause due to the diagnosis of obstetrics and gynecology, the female genitals are inflamed due to viral infection, and pregnancy is not possible. Therefore, after getting rid of the virus and gaining sufficient physical strength, a healing method was recommended to help her become pregnant, and the patient accepted it. According to the physical condition, menstrual pain was severe, the lower abdomen was cold, and the state of the uterus was not clear by ultrasound examination. After using contraception and taking the antiviral agent according to an embodiment of the present invention in a controlled amount for a total of 12 months, it was recommended to try pregnancy after 12 months. She became pregnant that week and gave birth to her first child in good health without any problems, and after 22 months without any additional care, she gave birth to her second child.

[Clinical trial 29] Viral progressive encephalopathy (9 years old, male)

The patient was diagnosed with a progressive brain lesion disorder caused by a virus at Samsung Medical Center because of a sudden high fever, and was taking antiepileptic drugs. The symptoms were accompanied by a decrease in cognitive and motor skills, and occasionally had minor seizures. The patient's mother was a trusted protector because she had experience helping the present inventors heal cleanly of atopic dermatitis, which had been suffering for over 20 years. Since this patient was already diagnosed with a brain disease caused by a virus, the antiviral agent according to the embodiment of the present invention was appropriately added or decreased for the first 24 months to eliminate the virus. It was observed that even if the epilepsy medication was reduced and stopped during the course, no epilepsy symptoms occurred, and the intelligence and motor ability recovered to normal. Also, at the 23rd month, it was confirmed that the virus-infected area, which had been blurry, no longer appeared in the regular brain examination conducted by Samsung Medical Center.

[Clinical trial 30] Brain lesion disorder (7 years old, female)

This patient is a girl who was diagnosed with a grade 2 intellectual disability. Intellectual disability was regarded as a viral brain lesion disorder of the central nervous system, and the antiviral agent according to an embodiment of the present invention was administered while increasing or decreasing the dose for 24 months. At first, he could not walk properly, so he had to hold hands around him, and he could not speak, and it was impossible to exchange or communicate emotions. Currently, he is growing up as a normal child who can run, jump with his feet together, play aegyo, and play with Sam. Even in this case, it is determined that the virus causing inflammation of the central nervous system by the antiviral agent according to an embodiment of the present invention is killed. In addition to intellectual disability, neurological diseases such as developmental disability, developmental delay, depression, attention deficit hyperactivity disorder (ADHD), insomnia, panic disorder, and cerebral lesion disorders such as obsessive compulsive disorder, are different from viral encephalopathy. However, as with viral encephalopathy, the virus enters the central nervous system and damages a part of the cranial nerve or prevents it from functioning properly. In addition, regardless of the disease name or symptoms, the cause is a disease that has progressed from central neuritis caused by a virus, so the necessary prescriptions are the same, only the healing period is different. In addition, it has been confirmed through several clinical cases that the more the infection occurs at a young age, the more severe the symptoms compared to the degree of infection, and the more severe the change in appearance, the longer the healing period.

[Clinical trial 31] Developmental disability (4 years old, male)

The patient was being managed at the Children's Mental Health Development Clinic at Seoul Medical Center. The results of the psychological education test conducted at Seoul Medical Center were actual age - 3 years and 2 months, living age - 16 months, and developmental index (DQ) - 42.1. For reference, the developmental index (DQ) is similar to IQ, where 100 is the standard, more than 100 is advanced development, and less than 100 is considered late. Another opinion was that they had difficulty performing tasks in a structured environment such as following language instructions and sitting, and that they had limited performance in items that imitate other people's language and behavior or that require challenge or repetition. For about 24 months, the antiviral agent according to an embodiment of the present invention was administered to this patient while appropriately increasing or decreasing the dose. As a result, in the progress report of the psychological education test, the actual age - 4 years and 5 months, the living age - 4 years and 1 month, the developmental index (DQ) - 92.5 showed a lot of improvement. In addition, it is possible to concentrate on the task by maintaining a seated position for a certain period of time, and to improve basic social skills necessary for interaction with others such as imitation and verbal expression, perception, fine muscle, large muscle, hand-eye coordination, and movement and verbal cognition. showed progress in basic learning skills such as concentration of attention, scissoring, drawing lines and shapes, and interest in and use of materials and toys.

[Clinical Trial 32] Muscular Dystrophy (5 years old, male)

A Chinese child living in Beijing, who was diagnosed with progressive muscular dystrophy and had been looking for a cure for over half a year in China, but was in a desperate state. Before the treatment by the antiviral agent according to an embodiment of the present invention, the growth state was sluggish and it was difficult to walk about 30-50 meters, so I had to rest and walk again. To climb the bed, he was unable to climb with his hands because he had no strength in his hands. It is also a case of intellectual decline as it is said that they played separately because they could not participate in class because they could not sit in kindergarten, and they did not get along with other children. When I touched the leg, there was no flesh under the knee, only the bones were bare, and the muscles in the calf were hardened like stones, and the muscles of the buttocks were also slightly stiff. He was also 82 centimeters tall, shorter than the other children. For 7 months, the antiviral agent according to an embodiment of the present invention was taken while increasing or decreasing the dose. After 7 months, she can walk for a few dozen minutes, hop lightly while holding her parents' hands, hop on her feet, climb on the bed, sit well in class in kindergarten, participate in class, and get along with children even though she is clumsy. In the legs, hip muscles are normal and calves have a lot of muscle, so there is no difference from normal people. Also, a lot of things that were hard to touch like stones under the calf muscles have been loosened, but they are still showing a hardness that is not normal. Miraculously, before taking the antiviral agent according to an embodiment of the present invention, he was 82 cm tall, much shorter than his peers, but grew by 27 cm to 109 cm in just 7 months, rather than other children. This is about 1/3 of his original height, and the cramped muscles in his legs hindered the growth of bones, but as the muscles loosened and his health improved, it seems that he grew in a short period of time. Muscular dystrophy (Muscular Dystrophy) is a hereditary and progressive myopathy, which has been known as a disease in which progressive muscle atrophy and muscle weakness appear, and there is currently no specific treatment method. Depending on the type, it starts from childhood to early adulthood, and it progresses more with age, causing difficulty in walking, resulting in kyphosis and breathing difficulties. may even die from However, about 20% of cases, such as facial scapulohumeral muscular dystrophy, have a relatively late onset and slow progression, leading to dependence on a wheelchair. Also, depending on the type, the IQ may decrease, and death is common due to respiratory failure due to invasion of the respiratory muscles or myocardium. However, while managing a patient with Muscular Dystrophy, the patient's condition was clearly improved, and it was determined that it was a treatable disease and a viral disease.

[Clinical trial 33] Cri du chat syndrome (5 years old, female)

Cri du chat syndrome is a congenital disease caused by chromosomal abnormalities whose main symptom is crying similar to that of a cat. Cri du chat syndrome was first reported in 1963, and appears because a part of the fifth chromosome is cut off, which interferes with ontogenesis and causes incomplete laryngeal development. Characteristic symptoms include crying similar to that of a cat, microcephaly, and intellectual disability. Other symptoms include a round face, wide forehead, myasthenia gravis, anomalies in palms, flat feet, and a short neck, and about 20% of them have congenital heart disease. As you get older, your cat's cry, myasthenia gravis, and round face may gradually disappear, and there is no specific treatment yet. This patient was not able to communicate at all before taking the antiviral agent according to an embodiment of the present invention, and was not able to get along with others, so he had severe stunting, so he was shorter and weighed less than his two-year-old brother. For 24 months, the antiviral agent according to an embodiment of the present invention was taken while appropriately adjusting the dose. After I started taking it, my growth improved, and after 24 months, I was much taller than my brother and weighed a lot, so I couldn't wear clothes of the same size. Also, when they ask me to take a picture now, they pose for me and they say that I get along better with others than before. Even in this case, it will be improved with prescriptions such as brain lesion disorder, developmental disorder, and developmental delay presumed to be viral central neuritis. From this, it was confirmed that Cri du chat syndrome is a treatable disease and a viral disease.

[Clinical trial 34] Down's syndrome (12 years old, female)

Down's syndrome is a typical genetic disease that causes mental retardation, physical malformations, systemic dysfunction, and growth disorders due to the presence of three chromosomes 21, two of which are normal. Characteristic facial deformities such as a small head, a round and flat face, a low nose, raised tails of the eyes, and the distance between the eyes are observed from the newborn and childhood period. The neck is short and thick, and the muscles are weak. Its development is slow, and it walks only after 2 years of age, and it is slow to speak and eventually grows into an adult, with an average IQ of 20-50. He does not grow well, so he is short even when he becomes an adult, and is often observed as obese. This patient is a patient who has applied the antiviral agent according to the embodiment of the present invention for 2 years to check whether the antiviral agent according to the embodiment of the present invention can cure Down's syndrome. Before the application of the antiviral agent according to an embodiment of the present invention, it is a typical Down's syndrome, and the level of intelligence is not talking about the current grade and class, but about the grade and class of last year. it was While the antiviral agent according to an embodiment of the present invention was taken for 24 months while appropriately increasing or decreasing the dose, an improvement was confirmed in only 4 months from the start of taking. One of the characteristics of Down's syndrome is that the forehead, nose, and lips are in a straight line. It is thought that the jaw protruded due to cerebral edema, but as the cerebral edema decreased, the jaw returned to normal. Also, in the process, the shoulders and neckline decreased, and at the same time, it was confirmed that the fingers grew specially. This is thought to be a change in the form of blood flowing down from the shoulders and head to the extremities. Down's syndrome patients' fingers are short and the thickness of the fingertips is sharply tapered. As the finger grows, the tip of the finger swells up like a frog's foot, and then the thickness gradually becomes the same. After 24 months, the level of intelligence has also developed so much that he can talk with his grandmother, who was his guardian, and develop to the point of nagging. Through this, it was determined that Down's syndrome causes various external body changes by causing viral central neuritis.

<Results of tracking effects on manufactured and sold products>

The applicant is selling the antiviral pill according to an embodiment of the present invention through a pharmacy. As a result of follow-up of patients administered by pharmacists who participated in the sale, the following symptom improvement effects were confirmed.

1) As a result of tracking the administration results for 1,000 influenza patients, symptom improvement effects were confirmed in 925 (92.5%) patients.

2) As a result of tracking the administration results for 500 rhinovirus patients, symptom improvement was confirmed in 453 (90.6%) patients.

3) As a result of tracking the administration results for 100 patients with herpes zoster, the improvement of symptoms was confirmed in 91 patients (91%).

4) As a result of tracking administration results for 100 patients with atopic dermatitis, improvement of symptoms was confirmed in 88 patients (88%).

5) As a result of tracking the administration results for 300 chronic rhinitis patients, improvement of symptoms was confirmed in 243 patients (81%).

6) As a result of tracking the administration results for 100 psoriasis patients, improvement of symptoms was confirmed in 79 patients (79%).

6) As a result of tracking the administration results for 100 hypertensive patients, improvement of symptoms was confirmed in 69 patients (69%).

6) As a result of tracking administration results for 100 chronic cystitis patients, improvement of symptoms was confirmed in 55 patients (55%).

6) As a result of tracking the administration results for 100 patients with periodontal disease, improvement of symptoms was confirmed in 85 patients (85%).

6) As a result of tracking the administration results for 100 patients with chronic myofascial disease, 43 patients (43%) showed improvement in symptoms.

Claims (1)

Maple syrup 1 to 11% by weight; 1 to 13% by weight of tabasheer, the sap of bamboo that is evaporated by strong heat in the process of making charcoal from bamboo; 20 to 40% by weight of yiyin; Xylitol 10-25% by weight; Vitamin C 1 to 8% by weight; Manuka honey 10-20% by weight; Frankincense 1 to 10% by weight; 1-10 wt% myrrh; An antiviral agent for the treatment or alleviation of influenza A virus comprising 0.1 to 5% by weight of propolis.